López-Medina E et al., 2021-04-13: Randomized double-blind placebo-controlled trial in 476 adults with mild COVID-19 in Cali, Colombia: five days of ivermectin 300 micrograms/kg/day did not shorten time to symptom resolution.
Among adults with mild COVID-19, a 5-day course of ivermectin, compared with placebo, did not significantly improve the time to resolution of symptoms.
López-Medina E et al., 2021-04-13: Randomized double-blind placebo-controlled trial in 476 adults with mild COVID-19 in Cali, Colombia: five days of ivermectin 300 micrograms/kg/day did not shorten time to symptom resolution. Randomized, double-blind, placebo-controlled trial, N=476 adults with mild COVID-19, Cali, Colombia, July-November 2020; ivermectin 300 micrograms/kg body weight per day for 5 days versus placebo; primary outcome time to resolution of symptoms. Conflicts: the first author reported grants from Sanofi Pasteur, GSK and Janssen and personal fees from Sanofi Pasteur during the conduct of the study (declared in the paper's disclosure section). NCT04405843. No drug-maker supplied product is disclosed in the record. Study type: randomized trial.
